Analysts Have Conflicting Sentiments on These Healthcare Companies: Dexcom (DXCM) and Pro Medicus Limited (OtherPMCUF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM) and Pro Medicus Limited (PMCUF).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dexcom (DXCM)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Dexcom on April 13 and set a price target of $85.00. The company’s shares closed last Tuesday at $62.95, close to its 52-week low of $62.34.
According to TipRanks.com, Chadha is a 2-star analyst with an average return of
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $86.50, which is a 38.0% upside from current levels. In a report issued on March 29, TipRanks – xAI also upgraded the stock to Buy with a $71.00 price target.
See the top stocks recommended by analysts >>
Pro Medicus Limited (PMCUF)
RBC Capital analyst Jackson Lee maintained a Hold rating on Pro Medicus Limited yesterday and set a price target of A$190.00. The company’s shares closed last Tuesday at $92.75.
Pro Medicus Limited has an analyst consensus of Strong Buy, with a price target consensus of $152.25, a 61.0% upside from current levels. In a report issued on March 30, TipRanks – OpenAI also downgraded the stock to Hold with a A$128.00 price target.
Read More on DXCM:
